Gabapentin
Product Images NDC 50436-3011

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50436-3011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl504363011)

This is a warning label for a medication called Gabapentin. It contains 90 tablets, each with a dosage of 600mg. The package was produced by Unit Dose Services LLC, with a lot number of "X000" and an expiration date of "X0000K".*

FDA Label Image

Spl-gabapentin-figure1 (Spl Gabapentin Figure1)

This is a graph showing the weekly mean pain scores observed during a study. The study had a 4-week dose titration period and a 4-week fixed dose period. The graph displays the placebo and gabapentin (taken at a dose of 3,600 mg/day) groups. The X-axis shows the weeks of the study, and the Y-axis shows the pain scores. The gabapentin group had a lower mean pain score than the placebo group.*

FDA Label Image

Spl-gabapentin-figure2 (Spl Gabapentin Figure2)

The text describes a chart showing the weekly mean pain scores observed in a study with three groups of participants: a placebo group and two groups who were given different doses of gabapentin. The study had a three-week period where the dose was increased, followed by a four-week period at a fixed dose. The chart shows seven weeks, including the baseline measurement.*

FDA Label Image

Spl-gabapentin-figure3 (Spl Gabapentin Figure3)

The figure shows the proportion of patients who had a reduction in pain score of more than 50% at the endpoint of the controlled PHN studies. The results are presented for two different studies, Study 1 and Study 2. The proportion of responders was higher for patients treated with GBP compared to those receiving placebo, with a statistically significant difference. The percentage of responders ranged from 50% to 90% depending on the group, with the highest proportion of responders found in the GBP group. The sample size for each group was 1,800 for GBP and 3,600 for placebo.*

FDA Label Image

Spl-gabapentin-figure4 (Spl Gabapentin Figure4)

FDA Label Image

Spl-gabapentin-formula (Spl Gabapentin Formula)

This appears to be a formula for calculating the estimated glomerular filtration rate (eGFR) using age, weight, and serum creatinine levels. However, the formula is incomplete as there are missing variables or coefficients. The has also turned '70' into 'Ol'.*

FDA Label Image

Spl-gabapentin-structure (Spl Gabapentin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.